Share Price and Basic Stock Data
Last Updated: February 14, 2026, 10:13 pm
| PEG Ratio | -3.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dhanvantri Jeevan Rekha Ltd operates in the Hospitals & Medical Services sector, with its stock currently priced at ₹25.0 and a market capitalization of ₹10.2 Cr. The company has shown a fluctuating revenue trend over recent quarters, with sales reported at ₹3.97 Cr in September 2022, increasing to ₹5.15 Cr by December 2023. The trailing twelve months (TTM) revenue stood at ₹22.88 Cr, reflecting growth from ₹17.68 Cr recorded in March 2023 and ₹16.77 Cr in March 2022. However, the operating profit margin (OPM) was negative at -1.20%, indicating challenges in cost management. The company’s sales over the years have shown variability, with the highest annual sales recorded at ₹22.65 Cr for the year ending March 2025, compared to ₹16.84 Cr in March 2019. This trend suggests a gradual recovery from previous low points, such as the drop to ₹9.78 Cr in March 2021, which may have been influenced by the pandemic’s impact on the healthcare sector.
Profitability and Efficiency Metrics
The profitability metrics for Dhanvantri Jeevan Rekha Ltd illustrate a mixed performance, with the company reporting a net profit of ₹0.10 Cr. The return on equity (ROE) was reported at a modest 5.20%, while the return on capital employed (ROCE) stood at 5.82%. The company’s operating profit has shown volatility, with a peak operating profit of ₹0.47 Cr in December 2023, but it faced challenges with negative operating profits in several quarters, notably a loss of ₹0.07 Cr in September 2025. The interest coverage ratio (ICR) is notably strong at 91.29x, indicating that the company comfortably covers its interest obligations, although it has not reported any borrowings, reflecting a conservative financial management approach. However, the negative operating profit margin in the recent quarter raises concerns about operational efficiency, which is critical in the competitive healthcare sector.
Balance Sheet Strength and Financial Ratios
Dhanvantri Jeevan Rekha Ltd maintains a solid balance sheet with total borrowings at ₹0.00 Cr, underscoring its debt-free status. Reserves have shown a slight increase, standing at ₹5.90 Cr as of September 2025, compared to ₹5.15 Cr in March 2023. The company’s current ratio is reported at 1.49, indicating adequate liquidity to meet short-term obligations, while the quick ratio is slightly lower at 1.44, suggesting that the company is well-positioned to cover its liabilities without relying on inventory. The price-to-book value ratio stands at 0.84x, which is below the typical sector range, potentially indicating that the stock is undervalued relative to its book value. Additionally, the asset turnover ratio is reported at 1.52, suggesting efficient use of assets in generating revenue, although improvements in operational efficiency are needed to enhance overall profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dhanvantri Jeevan Rekha Ltd reveals that promoters hold 19.65% of the shares, while the public holds a significant majority at 80.35%. This distribution indicates a relatively stable ownership structure, with a total of 1,665 shareholders as of September 2025, slightly down from 1,680 in March 2025. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could suggest limited institutional interest, which may impact liquidity and stock performance. However, the high public shareholding could enhance governance and accountability. The gradual increase in the number of shareholders over the years reflects growing interest in the company, albeit modestly, indicating potential investor confidence amid the challenges faced by the company in achieving profitability.
Outlook, Risks, and Final Insight
The outlook for Dhanvantri Jeevan Rekha Ltd remains cautiously optimistic, given its debt-free status and potential for revenue growth in the healthcare sector. However, persistent operational challenges, as reflected in its negative operating profit margins and fluctuating profitability metrics, pose significant risks. The company must focus on improving operational efficiency and managing costs to enhance profitability. Additionally, the lack of institutional interest could limit capital inflow, impacting the stock’s performance. To navigate these challenges, Dhanvantri Jeevan Rekha Ltd may benefit from strategic investments in operational improvements and marketing to attract more institutional investors. If it successfully addresses these issues, the company could position itself for sustainable growth in the evolving healthcare landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.6 Cr. | 139 | 187/120 | 117 | 2.52 % | 23.6 % | 20.7 % | 10.0 | |
| Global Longlife Hospital and Research Ltd | 14.1 Cr. | 13.4 | 33.0/11.6 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.71 Cr. | 9.39 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 106 Cr. | 56.3 | 98.7/52.2 | 23.2 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.8 Cr. | 3.49 | 5.97/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,430.00 Cr | 702.26 | 80.99 | 92.86 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.97 | 4.65 | 4.96 | 4.98 | 4.90 | 5.15 | 5.44 | 5.70 | 5.42 | 5.70 | 5.83 | 5.51 | 5.84 |
| Expenses | 4.04 | 4.48 | 4.73 | 4.75 | 4.87 | 4.68 | 5.43 | 5.45 | 5.18 | 5.51 | 5.79 | 5.37 | 5.91 |
| Operating Profit | -0.07 | 0.17 | 0.23 | 0.23 | 0.03 | 0.47 | 0.01 | 0.25 | 0.24 | 0.19 | 0.04 | 0.14 | -0.07 |
| OPM % | -1.76% | 3.66% | 4.64% | 4.62% | 0.61% | 9.13% | 0.18% | 4.39% | 4.43% | 3.33% | 0.69% | 2.54% | -1.20% |
| Other Income | 0.05 | 0.08 | 0.06 | 0.06 | 0.07 | 0.09 | 0.07 | 0.08 | 0.10 | 0.13 | 0.11 | 0.07 | 0.09 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.24 | 0.23 | 0.23 | 0.24 | 0.25 | 0.20 | 0.18 | 0.17 | 0.16 | 0.17 | 0.07 | 0.15 | 0.16 |
| Profit before tax | -0.26 | 0.02 | 0.06 | 0.05 | -0.15 | 0.36 | -0.10 | 0.16 | 0.17 | 0.15 | 0.08 | 0.06 | -0.14 |
| Tax % | 0.00% | 0.00% | 133.33% | 0.00% | 0.00% | 0.00% | -10.00% | 0.00% | 0.00% | 0.00% | 62.50% | 0.00% | 0.00% |
| Net Profit | -0.26 | 0.02 | -0.02 | 0.05 | -0.15 | 0.36 | -0.09 | 0.16 | 0.17 | 0.15 | 0.03 | 0.06 | -0.14 |
| EPS in Rs | -0.63 | 0.05 | -0.05 | 0.12 | -0.37 | 0.88 | -0.22 | 0.39 | 0.41 | 0.37 | 0.07 | 0.15 | -0.34 |
Last Updated: December 27, 2025, 7:01 am
Below is a detailed analysis of the quarterly data for Dhanvantri Jeevan Rekha Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 5.84 Cr.. The value appears strong and on an upward trend. It has increased from 5.51 Cr. (Jun 2025) to 5.84 Cr., marking an increase of 0.33 Cr..
- For Expenses, as of Sep 2025, the value is 5.91 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.37 Cr. (Jun 2025) to 5.91 Cr., marking an increase of 0.54 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Jun 2025) to -0.07 Cr., marking a decrease of 0.21 Cr..
- For OPM %, as of Sep 2025, the value is -1.20%. The value appears to be declining and may need further review. It has decreased from 2.54% (Jun 2025) to -1.20%, marking a decrease of 3.74%.
- For Other Income, as of Sep 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Jun 2025) to 0.09 Cr., marking an increase of 0.02 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.15 Cr. (Jun 2025) to 0.16 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.14 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Jun 2025) to -0.14 Cr., marking a decrease of 0.20 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -0.14 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Jun 2025) to -0.14 Cr., marking a decrease of 0.20 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.34. The value appears to be declining and may need further review. It has decreased from 0.15 (Jun 2025) to -0.34, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:51 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.26 | 7.97 | 9.26 | 11.16 | 13.74 | 16.84 | 18.21 | 9.78 | 16.77 | 17.68 | 20.46 | 22.65 | 22.88 |
| Expenses | 5.93 | 6.44 | 7.81 | 9.53 | 11.89 | 15.61 | 17.55 | 10.53 | 15.27 | 17.10 | 19.62 | 21.93 | 22.58 |
| Operating Profit | 1.33 | 1.53 | 1.45 | 1.63 | 1.85 | 1.23 | 0.66 | -0.75 | 1.50 | 0.58 | 0.84 | 0.72 | 0.30 |
| OPM % | 18.32% | 19.20% | 15.66% | 14.61% | 13.46% | 7.30% | 3.62% | -7.67% | 8.94% | 3.28% | 4.11% | 3.18% | 1.31% |
| Other Income | 0.21 | 0.44 | 0.31 | -0.11 | 0.14 | 0.12 | 0.16 | 0.18 | 0.21 | 0.24 | 0.29 | 0.41 | 0.40 |
| Interest | 0.01 | 0.08 | 0.08 | 0.18 | 0.22 | 0.11 | 0.04 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.67 | 0.36 | 0.27 | 0.37 | 1.10 | 1.13 | 1.10 | 1.04 | 1.02 | 0.96 | 0.87 | 0.56 | 0.55 |
| Profit before tax | 0.86 | 1.53 | 1.41 | 0.97 | 0.67 | 0.11 | -0.32 | -1.63 | 0.67 | -0.15 | 0.25 | 0.56 | 0.15 |
| Tax % | 39.53% | 29.41% | 32.62% | 43.30% | -7.46% | 63.64% | -15.62% | -12.88% | 28.36% | 46.67% | 36.00% | 8.93% | |
| Net Profit | 0.52 | 1.07 | 0.95 | 0.55 | 0.73 | 0.05 | -0.26 | -1.42 | 0.49 | -0.22 | 0.17 | 0.51 | 0.10 |
| EPS in Rs | 1.27 | 2.61 | 2.32 | 1.34 | 1.78 | 0.12 | -0.63 | -3.46 | 1.20 | -0.54 | 0.41 | 1.24 | 0.25 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.77% | -11.21% | -42.11% | 32.73% | -93.15% | -620.00% | -446.15% | 134.51% | -144.90% | 177.27% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -116.98% | -30.89% | 74.83% | -125.88% | -526.85% | 173.85% | 580.66% | -279.41% | 322.17% | 22.73% |
Dhanvantri Jeevan Rekha Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 4% |
| 3 Years: | 11% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 32% |
| 3 Years: | 1% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 26% |
| 3 Years: | 16% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -1% |
| 3 Years: | 2% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: February 1, 2026, 2:40 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 |
| Reserves | 2.50 | 4.29 | 5.25 | 5.79 | 6.52 | 6.57 | 6.30 | 4.88 | 5.37 | 5.15 | 5.32 | 5.98 | 5.90 |
| Borrowings | 0.09 | 0.00 | 0.00 | 1.94 | 1.95 | 0.10 | 0.10 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 1.70 | 2.52 | 3.29 | 4.53 | 3.79 | 4.53 | 4.30 | 4.76 | 4.84 | 4.56 | 5.55 | 4.65 | 5.66 |
| Total Liabilities | 8.44 | 10.96 | 12.69 | 16.41 | 16.41 | 15.35 | 14.85 | 13.86 | 14.36 | 13.86 | 15.02 | 14.78 | 15.71 |
| Fixed Assets | 4.57 | 5.05 | 7.80 | 12.07 | 12.28 | 11.44 | 10.68 | 9.72 | 8.85 | 8.54 | 8.14 | 8.41 | 8.80 |
| CWIP | 0.00 | 1.44 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 3.87 | 4.47 | 4.89 | 4.34 | 4.13 | 3.79 | 4.17 | 4.14 | 5.51 | 5.32 | 6.88 | 6.37 | 6.91 |
| Total Assets | 8.44 | 10.96 | 12.69 | 16.41 | 16.41 | 15.35 | 14.85 | 13.86 | 14.36 | 13.86 | 15.02 | 14.78 | 15.71 |
Below is a detailed analysis of the balance sheet data for Dhanvantri Jeevan Rekha Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.15 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.15 Cr..
- For Reserves, as of Sep 2025, the value is 5.90 Cr.. The value appears to be declining and may need further review. It has decreased from 5.98 Cr. (Mar 2025) to 5.90 Cr., marking a decrease of 0.08 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 5.66 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.65 Cr. (Mar 2025) to 5.66 Cr., marking an increase of 1.01 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15.71 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.78 Cr. (Mar 2025) to 15.71 Cr., marking an increase of 0.93 Cr..
- For Fixed Assets, as of Sep 2025, the value is 8.80 Cr.. The value appears strong and on an upward trend. It has increased from 8.41 Cr. (Mar 2025) to 8.80 Cr., marking an increase of 0.39 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 6.91 Cr.. The value appears strong and on an upward trend. It has increased from 6.37 Cr. (Mar 2025) to 6.91 Cr., marking an increase of 0.54 Cr..
- For Total Assets, as of Sep 2025, the value is 15.71 Cr.. The value appears strong and on an upward trend. It has increased from 14.78 Cr. (Mar 2025) to 15.71 Cr., marking an increase of 0.93 Cr..
Notably, the Reserves (5.90 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 1.24 | 1.53 | 1.45 | -0.31 | -0.10 | 1.13 | 0.56 | -0.82 | 1.50 | 0.58 | 0.84 | 0.72 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16.09 | 15.11 | 20.50 | 11.45 | 17.80 | 22.32 | 9.02 | 39.93 | 37.22 | 50.58 | 31.22 | 29.01 |
| Inventory Days | 11.70 | 17.77 | 11.99 | |||||||||
| Days Payable | 0.00 | 0.00 | 0.00 | |||||||||
| Cash Conversion Cycle | 16.09 | 15.11 | 20.50 | 11.45 | 29.50 | 40.09 | 21.00 | 39.93 | 37.22 | 50.58 | 31.22 | 29.01 |
| Working Capital Days | 68.37 | 66.86 | 56.76 | -35.32 | -26.83 | -17.34 | -32.27 | -53.37 | -25.47 | -3.10 | -32.29 | -16.60 |
| ROCE % | 14.04% | 19.76% | 16.70% | 14.94% | 7.27% | 1.88% | -2.62% | -16.39% | 7.41% | -1.49% | 2.77% | 5.82% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.60 | 0.40 | -0.53 | 0.01 | -3.47 |
| Diluted EPS (Rs.) | 1.60 | 0.40 | -0.53 | 0.01 | -3.47 |
| Cash EPS (Rs.) | 2.58 | 2.48 | 1.78 | 3.63 | -0.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.39 | 22.81 | 22.41 | 22.93 | 21.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.39 | 22.81 | 22.41 | 22.93 | 21.75 |
| Revenue From Operations / Share (Rs.) | 54.53 | 49.26 | 42.58 | 40.38 | 23.55 |
| PBDIT / Share (Rs.) | 2.73 | 2.71 | 1.97 | 4.11 | -1.36 |
| PBIT / Share (Rs.) | 1.37 | 0.62 | -0.33 | 1.66 | -3.87 |
| PBT / Share (Rs.) | 1.34 | 0.61 | -0.34 | 1.62 | -3.92 |
| Net Profit / Share (Rs.) | 1.22 | 0.39 | -0.52 | 1.18 | -3.43 |
| PBDIT Margin (%) | 5.00 | 5.51 | 4.62 | 10.17 | -5.76 |
| PBIT Margin (%) | 2.50 | 1.27 | -0.77 | 4.11 | -16.44 |
| PBT Margin (%) | 2.45 | 1.24 | -0.81 | 4.01 | -16.66 |
| Net Profit Margin (%) | 2.23 | 0.80 | -1.22 | 2.92 | -14.55 |
| Return on Networth / Equity (%) | 4.99 | 1.74 | -2.32 | 5.14 | -15.75 |
| Return on Capital Employeed (%) | 4.85 | 2.33 | -1.25 | 5.69 | -16.04 |
| Return On Assets (%) | 3.42 | 1.10 | -1.56 | 3.41 | -11.11 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.52 | 1.42 | 1.25 | 1.23 | 0.71 |
| Current Ratio (X) | 1.49 | 1.30 | 1.24 | 1.66 | 0.74 |
| Quick Ratio (X) | 1.44 | 1.27 | 1.19 | 1.61 | 0.71 |
| Inventory Turnover Ratio (X) | 163.30 | 0.00 | 0.00 | 0.00 | 23.45 |
| Interest Coverage Ratio (X) | 91.29 | 224.14 | 117.93 | 104.40 | -26.69 |
| Interest Coverage Ratio (Post Tax) (X) | 41.79 | 33.85 | -30.24 | 30.99 | -66.31 |
| Enterprise Value (Cr.) | 6.04 | 7.20 | 4.55 | 5.13 | 2.26 |
| EV / Net Operating Revenue (X) | 0.26 | 0.35 | 0.25 | 0.30 | 0.23 |
| EV / EBITDA (X) | 5.33 | 6.38 | 5.56 | 3.01 | -4.01 |
| MarketCap / Net Operating Revenue (X) | 0.37 | 0.49 | 0.30 | 0.41 | 0.31 |
| Price / BV (X) | 0.84 | 1.07 | 0.58 | 0.72 | 0.34 |
| Price / Net Operating Revenue (X) | 0.37 | 0.49 | 0.30 | 0.41 | 0.31 |
| EarningsYield | 0.05 | 0.01 | -0.04 | 0.07 | -0.45 |
After reviewing the key financial ratios for Dhanvantri Jeevan Rekha Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 5. It has increased from 0.40 (Mar 24) to 1.60, marking an increase of 1.20.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 5. It has increased from 0.40 (Mar 24) to 1.60, marking an increase of 1.20.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.58. This value is below the healthy minimum of 3. It has increased from 2.48 (Mar 24) to 2.58, marking an increase of 0.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.39. It has increased from 22.81 (Mar 24) to 24.39, marking an increase of 1.58.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.39. It has increased from 22.81 (Mar 24) to 24.39, marking an increase of 1.58.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 54.53. It has increased from 49.26 (Mar 24) to 54.53, marking an increase of 5.27.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.73. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 2.73, marking an increase of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 1.37, marking an increase of 0.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.34. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 1.34, marking an increase of 0.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 2. It has increased from 0.39 (Mar 24) to 1.22, marking an increase of 0.83.
- For PBDIT Margin (%), as of Mar 25, the value is 5.00. This value is below the healthy minimum of 10. It has decreased from 5.51 (Mar 24) to 5.00, marking a decrease of 0.51.
- For PBIT Margin (%), as of Mar 25, the value is 2.50. This value is below the healthy minimum of 10. It has increased from 1.27 (Mar 24) to 2.50, marking an increase of 1.23.
- For PBT Margin (%), as of Mar 25, the value is 2.45. This value is below the healthy minimum of 10. It has increased from 1.24 (Mar 24) to 2.45, marking an increase of 1.21.
- For Net Profit Margin (%), as of Mar 25, the value is 2.23. This value is below the healthy minimum of 5. It has increased from 0.80 (Mar 24) to 2.23, marking an increase of 1.43.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.99. This value is below the healthy minimum of 15. It has increased from 1.74 (Mar 24) to 4.99, marking an increase of 3.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.85. This value is below the healthy minimum of 10. It has increased from 2.33 (Mar 24) to 4.85, marking an increase of 2.52.
- For Return On Assets (%), as of Mar 25, the value is 3.42. This value is below the healthy minimum of 5. It has increased from 1.10 (Mar 24) to 3.42, marking an increase of 2.32.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.52. It has increased from 1.42 (Mar 24) to 1.52, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has increased from 1.30 (Mar 24) to 1.49, marking an increase of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 1.44. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.44, marking an increase of 0.17.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 163.30. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 163.30, marking an increase of 163.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 91.29. This value is within the healthy range. It has decreased from 224.14 (Mar 24) to 91.29, marking a decrease of 132.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 41.79. This value is within the healthy range. It has increased from 33.85 (Mar 24) to 41.79, marking an increase of 7.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.04. It has decreased from 7.20 (Mar 24) to 6.04, marking a decrease of 1.16.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has decreased from 0.35 (Mar 24) to 0.26, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 5.33. This value is within the healthy range. It has decreased from 6.38 (Mar 24) to 5.33, marking a decrease of 1.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.37, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.07 (Mar 24) to 0.84, marking a decrease of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.37, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhanvantri Jeevan Rekha Ltd:
- Net Profit Margin: 2.23%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.85% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.99% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 41.79
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.44
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 87.2 (Industry average Stock P/E: 80.99)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.23%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 1, Saket, Meerut Uttar Pradesh 250003 | dhanvantrihospital@gmail.com http://www.dhanvantrihospital.in |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Shalini Sharma | Managing Director |
| Mr. Premjit Singh Kashyap | Director |
| Mrs. Meenaakshi Elhence | Director |
| Mr. Tulsi Prasad Sharma | Director |
| Dr. Anil Elhence | Director |
| Mrs. Rowena Sharma | Director |
| Mr. Mohd Harris | Independent Director |
| Mr. Amitabh Krishna Bhatia | Independent Director |
| Mr. Ravi Karan | Independent Director |
FAQ
What is the intrinsic value of Dhanvantri Jeevan Rekha Ltd?
Dhanvantri Jeevan Rekha Ltd's intrinsic value (as of 15 February 2026) is ₹66.24 which is 158.75% higher the current market price of ₹25.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹10.5 Cr. market cap, FY2025-2026 high/low of ₹35.9/16.5, reserves of ₹5.90 Cr, and liabilities of ₹15.71 Cr.
What is the Market Cap of Dhanvantri Jeevan Rekha Ltd?
The Market Cap of Dhanvantri Jeevan Rekha Ltd is 10.5 Cr..
What is the current Stock Price of Dhanvantri Jeevan Rekha Ltd as on 15 February 2026?
The current stock price of Dhanvantri Jeevan Rekha Ltd as on 15 February 2026 is ₹25.6.
What is the High / Low of Dhanvantri Jeevan Rekha Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dhanvantri Jeevan Rekha Ltd stocks is ₹35.9/16.5.
What is the Stock P/E of Dhanvantri Jeevan Rekha Ltd?
The Stock P/E of Dhanvantri Jeevan Rekha Ltd is 87.2.
What is the Book Value of Dhanvantri Jeevan Rekha Ltd?
The Book Value of Dhanvantri Jeevan Rekha Ltd is 24.5.
What is the Dividend Yield of Dhanvantri Jeevan Rekha Ltd?
The Dividend Yield of Dhanvantri Jeevan Rekha Ltd is 0.00 %.
What is the ROCE of Dhanvantri Jeevan Rekha Ltd?
The ROCE of Dhanvantri Jeevan Rekha Ltd is 5.82 %.
What is the ROE of Dhanvantri Jeevan Rekha Ltd?
The ROE of Dhanvantri Jeevan Rekha Ltd is 5.20 %.
What is the Face Value of Dhanvantri Jeevan Rekha Ltd?
The Face Value of Dhanvantri Jeevan Rekha Ltd is 10.0.